Effectiveness of Platelet-Rich Plasma Therapy in Androgenic Alopecia-A Meta-Analysis.
Simona Roxana GeorgescuAndreea AmuzescuCristina Iulia MitranMadalina Irina MitranClara MateiCarolina ConstantinMircea TampaMonica Teodora NeaguPublished in: Journal of personalized medicine (2022)
Platelet-rich plasma (PRP) represents a novel therapy tested and is used more and more frequently in dermatology and cosmetic surgery for a variety of conditions, including androgenic alopecia (AGA), a common condition with a complex pathogenesis involving genetic factors, hormonal status and inflammation. We performed an extensive literature search which retrieved 15 clinical trials concerning the use in AGA of PRP therapy, alone or in combination, in male, female or mixed patient groups. A quantitative statistical meta-analysis of n = 17 trial groups proved significant increases in hair density from 141.9 ± 108.2 to 177.5 ± 129.7 hairs/cm 2 (mean ± SD) following PRP ( p = 0.0004). To the best of our knowledge, this is the first meta-analysis that proved a statistically significant correlation between the number of PRP treatments per month and the percentage change in hair density ( r = 0.5, p = 0.03), as well as a negative correlation between the mean age of treatment group and the percentage change in hair density ( r = -0.56, p = 0.016). Other factors considered for analysis were the PRP preparation method, amount used per treatment, hair diameter, terminal hairs and pull test. We conclude that PRP represents a valuable and effective therapy for AGA in both males and females if patients are rigorously selected.
Keyphrases
- platelet rich plasma
- systematic review
- clinical trial
- end stage renal disease
- healthcare
- chronic kidney disease
- minimally invasive
- randomized controlled trial
- newly diagnosed
- oxidative stress
- ejection fraction
- high resolution
- study protocol
- gene expression
- case report
- adipose tissue
- coronary artery disease
- coronary artery bypass
- replacement therapy
- stem cells
- mesenchymal stem cells
- patient reported outcomes
- mass spectrometry
- atrial fibrillation
- open label
- skeletal muscle
- metabolic syndrome
- insulin resistance
- placebo controlled